Completed PHASE2 INTERVENTIONAL 1-arm NCT00138736

Study on Mannan Binding Lectin (MBL) Substitution in MBL-Deficient Children With Chemotherapy-Induced Neutropenia

Phase II Study on Mannan Binding Lectin (MBL) Substitution in MBL-Deficient Children With Chemotherapy-Induced Neutropenia

Sponsor: Landsteiner Foundation for Blood Transfusion

Conditions MBL-Deficient Neutropenia

Interventions Mannan Binding Lectin Mannan Binding Lectin (MBL)

Updated 7 times since 2017 Last updated: Aug 29, 2007 Started: Apr 30, 2004 Completion: Oct 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on MBL-Deficient and Neutropenia, this trial is completed. The trial is conducted by Landsteiner Foundation for Blood Transfusion and has accumulated 7 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Jan 2022 [monthly]

Completed PHASE2
Jul 2019 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jul 2019 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Landsteiner Foundation for Blood Transfusion
Prothya Biosolutions

Data source: Prothya Biosolutions

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Amsterdam, Netherlands
• Rotterdam, Netherlands